Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques

Virology

Volumn 440, Issue 2, 2013, Pages 210-221

  Demberg, Thorsten ^a   Brocca Cofano, Egidio ^a   Kuate, Seraphin ^a   Aladi, Stanley ^a   Vargas Inchaustegui, Diego A ^a   Venzon, David ^a   Kalisz, Irene ^b   Kalyanaraman, V S ^b   Lee, Eun Mi ^b   Pal, Ranajit ^b   DiPasquale, Janet ^a   Ruprecht, Ruth M ^c   Montefiori, David C ^d   Srivastava, Indresh ^e   Barnett, Susan W ^e   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

ADCC; HIV Envelope; HIV Tat; HIV vaccine; Rhesus macaque; SHIV challenge

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NEUTRALIZING ANTIBODY; RECOMBINANT TAT PROTEIN; RECOMBINANT VACCINE; RECOMBINANT VIRUS ENVELOPE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA SEQUENCE; SEQUENCE ANALYSIS; T LYMPHOCYTE; VIREMIA; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; GENE PRODUCTS, ENV; GENE PRODUCTS, TAT; HUMANS; IMMUNOLOGIC MEMORY; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA;

HUMAN ADENOVIRUS TYPE 5; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84876797653     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.02.024     Document Type: Article

References (46)

1. Asmuth D.M., Brown E.L., DiNubile M.J., Sun X., del Rio C., Harro C., Keefer M.C., Kublin J.G., Dubey S.A., Kierstead L.S., Casimiro D.R., Shiver J.W., Robertson M.N., Quirk E.K., Mehrotra D.V. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J. Infect. Dis. 2010, 201:132-141.
2. Brocca-Cofano E., McKinnon K., Demberg T., Venzon D., Hidajat R., Xiao P., Daltabuit-Test M., Patterson L.J., Robert-Guroff M. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011, 29:3310-3319.
3. Caputo A., Gavioli R., Bellino S., Longo O., Tripiciano A., Francavilla V., Sgadari C., Paniccia G., Titti F., Cafaro A., Ferrantelli F., Monini P., Ensoli F., Ensoli B. HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int. Rev. Immunol. 2009, 28:285-334.
4. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N., Hakim J.G., Kumwenda J., Grinsztejn B., Pilotto J.H.S., Godbole S.V., Mehendale S., Chariyalertsak S., Santos B.R., Mayer K.H., Hoffman I.F., Eshleman S.H., Piwowar-Manning E., Wang L., Makhema J., Mills L.A., de Bruyn G., Sanne I., Eron J., Gallant J., Havlir D., Swindells S., Ribaudo H., Elharrar V., Burns D., Taha T.E., Nielsen-Saines K., Celentano D., Essex M., Fleming T.R., for the HPTN 052 Study Team Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 2011, 365:493-505.
5. De Gregorio E., D'Oro U., Wack A. Immunology of TLR-independent vaccine adjuvants. Curr. Opin. Immunol. 2009, 21:339-345.
6. Demberg T., Brocca-Cofano E., Xiao P., Venzon D., Vargas-Inchaustegui D., Lee E.M., Kalisz I., Kalyanaraman V.S., DiPasquale J., McKinnon K., Robert-Guroff M. Dynamics of memory B-cell populations in blood, lymph node and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J. Virol. 2012, 86:12591-12604.
7. Demberg T., Ettinger A.C., Aladi S., McKinnon K., Kuddo T., Venzon D., Patterson L.J., Phillips T.M., Robert-Guroff M. Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory. Vaccine 2011, 29:6017-6028.
8. Demberg T., Florese R.H., Heath M.J., Larsen K., Kalisz I., Kalyanaraman V.S., Lee E.M., Pal R., Venzon D., Grant R., Patterson L.J., Korioth-Schmitz B., Buzby A., Dombagoda D., Montefiori D.C., Letvin N.L., Cafaro A., Ensoli B., Robert-Guroff M. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2007, 81:3414-3427.
9. Fanales-Belasio E., Moretti S., Fiorelli V., Tripiciano A., Pavone Cossut M.R., Scoglio A., Collacchi B., Nappi F., Macchia I., Bellino S., Francavilla V., Caputo A., Barillari G., Magnani M., Laguardia M.E., Cafaro A., Titti F., Monini P., Ensoli F., Ensoli B. HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J. Immunol. 2009, 182:2888-2897.
10. Ferrantelli F., Maggiorella M.T., Schiavoni I., Sernicola L., Olivieri E., Farcomeni S., Pavone-Cossut M.R., Moretti S., Belli R., Collacchi B., Srivastava I.K., Titti F., Cafaro A., Barnett S.W., Ensoli B. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Vaccine 2011, 29:2918-2932.
11. Florese R.H., Demberg T., Xiao P., Kuller L., Larsen K., Summers L.E., Venzon D., Cafaro A., Ensoli B., Robert-Guroff M. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol. 2009, 182:3718-3727.
12. Gomez-Roman V.R., Florese R.H., Patterson L.J., Peng B., Venzon D., Aldrich K., Robert-Guroff M. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Meth. 2006, 308:53-67.
13. Ganguly S., Manicassamy S., Blackwell J., Pulendran B., Amara R.R. Adenovirus type 5 induces vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells. Mucosal Immunol. 2011, 4:528-538.
14. Gomez-Roman V.R., Patterson L.J., Venzon D., Liewehr D., Aldrich K., Florese R., Robert-Guroff M. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 2005, 174:2185-2189.
15. Grossman Z., Meier-Schellersheim M., Paul W.E., Picker L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat. Med. 2006, 12:289-295.
16. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., Coyne-Johnson L., Whizin N., Oswald K., Shoemaker R., Swanson T., Legasse A.W., Chiuchiolo M.J., Parks C.L., Axthelm M.K., Nelson J.A., Jarvis M.A., Piatak M., Lifson J.D., Picker L.J. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
17. Hardstedt M., Finnegan C.P., Kirchhof N., Hyland K.A., Wijkstrom M., Murtaugh M.P., et al. Post-transplant upregulation of chemokine messenger RNA in non-human primate recipients of intraportal pig islet xenografts. Xenotransplantation 2005, 12:293-302.
18. Hartman Z.C., Appledorn D.M., Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 2008, 132:1-14.
19. Haynes B.F., Moody M.A., Liao H.X., Verkoczy L., Tomaras G.D. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol. Med. 2011, 17:108-116.
20. Hidajat R., Xiao P., Zhou Q., Venzon D., Summers L.E., Kalyanaraman V.S., Montefiori D.C., Robert-Guroff M. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 2009, 83:791-801.
21. Higginbotham J.N., Seth P., Blaese R.M., Ramsey W.J. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum. Gene Ther. 2002, 13:129-141.
22. Hofmann-Lehmann R., Vlasak J., Williams A.L., Chenine A.L., McClure H.M., Anderson D.C., O'Neil S., Ruprecht R.M. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 2003, 17:157-166.
23. Hofmann-Lehmann R., Williams A.L., Swenerton R.K., Li P.L., Rasmussen R.A., Chenine A.L., et al. Quantitation of simian cytokine and beta-chemokine mRNAs, using real-time reverse transcriptase-polymerase chain reaction: variations in expression during chronic primate lentivirus infection. AIDS Res. Hum. Retroviruses 2002, 18:627-639.
24. Ishii K.J., Akira S. Toll or Toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 2007, 27:363-371.
25. Kaufman D.R., Liu J., Carville A., Mansfield K.G., Havenga M.J., Goudsmit J., Barouch D.H. Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J. Immunol. 2008, 181:4188-4198.
26. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., McDermott A.B., Schultz A., Zamb T.J., Boyle R., Desrosiers R.C. HIV vaccine design: insights from live attenuated SIV vaccines. Nat. Immunol. 2006, 7:19-23.
27. Medeiros M., Sharma V.K., Ding R., Yamaji K., Li B., Muthukumar T., et al. Optimization of RNA yield, purity and mRNA copy number by treatment of urine cell pellets with RNAlater. J. Immunol. Methods 2003, 279:135-142.
28. Monini P., Cafaro A., Srivastava I.K., Moretti S., Sharma V.A., Andreini C., Chiozzini C., Ferrantelli F., Cossut M.R., Tripiciano A., Nappi F., Longo O., Bellino S., Picconi O., Fanales-Belasio E., Borsetti A., Toschi E., Schiavoni I., Bacigalupo I., Kan E., Sernicola L., Maggiorella M.T., Montin K., Porcu M., Leone P., Leone P., Collacchi B., Palladino C., Ridolfi B., Falchi M., Macchia I., Ulmer J.B., Buttò S., Sgadari C., Magnani M., Federico M.P., Titti F., Banci L., Dallocchio F., Rappuoli R., Ensoli F., Barnett S.W., Garaci E., Ensoli B. HIV-1 Tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. PLoS One 2012, 7:e48781.
29. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Current Protocols in Immunology 2004, 12.11.1-12.11.15. JohnWiley & Sons. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, R. Coico (Eds.).
30. Morefield G.L., Sokolovska A., Jiang D., HogenEsch H., Robinson J.P., Hem S.L. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005, 23:1588-1595.
31. Nishimura Y., Igarashi T., Donau O.K., Buckler-White A., Buckler C., Lafont B.A.P., Goeken R.M., Goldstein S., Hirsch V.M., Martin M.A. Highly pathogenic SHIVs andSIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc. Nat. Acad. Sci. U.S.A. 2004, 101:12324-12329.
32. Patterson L.J., Kuate S., Daltabuit-Test M., Li A., Xiao P., McKinnon K., Dipasquale J., Cristillo A.D., Venzon D., Haase A., Robert-Guroff M. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin. Vac. Immunol. 2012, 19:629-637.
33. Patterson L.J., Malkevitch N., Pinczewski J., Venzon D., Lou Y., Peng B., Munch C., Leonard M., Richardson E., Aldrich K., Kalyanaraman V.S., Pavlakis G.N., Robert-Guroff M. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J. Virol. 2003, 77:8607-8620.
34. Peng B., Wang L.R., Gomez-Roman V.R., Davis-Warren A., Montefiori D.C., Kalyanaraman V.S., Venzon D., Zhao J., Kan E., Rowell T.J., Murthy K.K., Srivastava I., Barnett S.W., Robert-Guroff M. Replicating rather than non-replicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high titer antibodies. J. Virol. 2005, 79:10200-10209.
35. Qureshi H., Ma Z.M., Huang Y., Hodge G., Thomas M.A., Dipasquale J., Desilva V., Fritts L., Bett A.J., Casimiro D.R., Shiver J.W., Robert-Guroff M., Robertson M.N., McChesney M.B., Gilbert P.B., Miller C.J. Low-dose penile SIVmac251 exposure of rhesus macaques infected with Adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb Step trialof a similar HIV-1 vaccine. J. Virol. 2012, 86:2239-2250.
36. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220.
37. Siddappa N.B., Watkins J.D., Wassermann K.J., Song R., Wang W., Kramer V.G., Lakhashe S., Santosuosso M., Poznansky M.C., Novembre F.J., Villinger F., Else J.G., Montefiori D.C., Rasmussen R.A., Ruprecht R.M. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect Env evolution and to develop AIDS vaccines in primate models. PLoS One 2010, 5(7):e11689.
38. Song R.J., Chenine A.L., Rasmussen R.A., Ruprecht C.R., Mirshahidi S., Grisson R.D., Xu W., Whitney J.B., Goins L.M., Ong H., Li P.L., Shai-Kobiler E., Wang T., McCann C.M., Zhang H., Wood C., Kankasa C., Secor W.E., McClure H.M., Strobert E., Else J.G., Ruprecht R.M. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J. Virol. 2006, 80:8729-8738.
39. Sun Y., Santra S., Buzby A.P., Mascola J.R., Nabel G.J., Letvin N.L. Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys. Virology 2010, 406:48-55.
40. Toapanta F.R., Craigo J.K., Montelaro R.C., Ross T.M. Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope. Curr. HIV Res. 2007, 5:199-209.
41. mac251 challenge. J. Virol. 2012, 86:4644-4657.
42. Xiao P., Zhao J., Patterson L.J., Brocca-Cofano E., Venzon D., Kozlowski P.A., Hidajat R., Demberg T., Robert-Guroff M. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2010, 84:7161-7173.
43. Zhang Y., Lou B., Lal R.B., Gettie A., Marx P.A., Moore J.P. Use of inhibitors to evaluate coreceptor usage by simian and simian-human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 2000, 74:6893-6910.
44. Zhao J., Lai L., Amara R.R., Montefiori D.C., Villinger F., Chennareddi L., Wyatt L.S., Moss B., Robinson H.L. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J. Virol. 2009, 83:4102-4111.
45. Zhou Q., Hidajat R., Peng B., Venzon D., Aldrich M.K., Richardson E., Lee E.M., Kalyanaraman V.S., Grimes G., Gomez-Roman V.R., Summers L.E., Malkevich N., Robert-Guroff M. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine 2007, 25:8021-8035.
46. Zsengeller Z., Otake K., Hossain S.A., Berclaz P.Y., Trapnell B.C. Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection. J. Virol. 2000, 74:9655-9667.